Do GLP-1 drugs increase the chance of pregnancy?

Two effects point that way — restored ovulation from metabolic improvement, and for tirzepatide specifically, reduced oral contraceptive absorption.

Are these medicines approved in pregnancy?

No. The Danish cohort's background notes that inadvertent periconceptional exposure nonetheless occurs frequently.

GLP-1 & Incretin Science

Restored Fertility and Reduced Contraceptive Absorption

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Two independent effects converge in the same population. Weight loss and improved insulin sensitivity can restore ovulation, making conception more likely. Separately, tirzepatide reduces oral contraceptive absorption. Both push in the same direction, and neither is visible to the person affected.

Key facts

Mechanism 1: Restored ovulation via metabolic improvement
Mechanism 2: Reduced oral contraceptive absorption
Mechanism 2 is: Tirzepatide-specific, not class-wide
Peak ethinyl estradiol: Reduced ~59% in reported data
Registry observation: Inadvertent exposure occurs frequently
Approved in pregnancy: No

Why convergence is the point

Either effect alone would be worth knowing. Together they compound: a population becoming more fertile at the same time as one form of contraception becomes less reliable. The two arise from completely unrelated pharmacology — one from metabolic improvement, one from delayed gastric emptying — and they happen to act on the same people at the same time.

The first mechanism, restated briefly

Insulin resistance and obesity disrupt ovulation, particularly in polycystic ovary syndrome. Substantial weight reduction and improved insulin sensitivity can restore ovulatory cycling. Someone whose cycles were irregular or absent may become fertile again without anything signalling that it has happened.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The second mechanism, and its limits

Tirzepatide's greater delay in gastric emptying reduces absorption of oral contraceptives — reported peak reductions of 55 to 66% across the hormone components with overall exposure down around 20%. This is tirzepatide-specific. Semaglutide, liraglutide and dulaglutide did not show it, so the convergence applies with full force to one compound and only partly to others.

Why neither is perceptible

Restored ovulation produces no symptom announcing itself, and reduced absorption of a tablet produces no sensation at all. Both changes are silent, which is why they are addressed through labelling and clinical discussion rather than left to be noticed.

What the registry data indicates about scale

The Danish nationwide cohort study of periconceptional exposure states in its background that these agents are rapidly expanding among reproductive-age women and that inadvertent periconceptional exposure occurs frequently. That is a description of what is already happening at population scale, not a projection.

The regulatory position, and the boundary

These medicines are not approved for use in pregnancy. Everything here describes licensed medicines prescribed and monitored clinically, and reproductive decisions belong with a clinician rather than an article. Nothing supplied on this site is a GLP-1 receptor agonist, affects fertility or contraception, or has any place in any of this.

Quick reference

Effect	Mechanism	Applies to
Restored ovulation	Weight loss, insulin sensitivity	The class, via weight change
Reduced OC absorption	Delayed gastric emptying	Tirzepatide specifically

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Do GLP-1 drugs increase the chance of pregnancy?: Two effects point that way — restored ovulation from metabolic improvement, and for tirzepatide specifically, reduced oral contraceptive absorption.
Does the contraceptive effect apply to all of them?: No. It is tirzepatide-specific; semaglutide, liraglutide and dulaglutide did not show it.
Are these medicines approved in pregnancy?: No. The Danish cohort's background notes that inadvertent periconceptional exposure nonetheless occurs frequently.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum